GIP and type 2 diabetes mellitus: Tirzepatide (Figure 17) is a state-of-the-art investigational dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, tailored specifically for treating type 2 diabetes.